143 related articles for article (PubMed ID: 36012384)
21. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
22. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
23. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
Evangelista L; Cimitan M; Hodolič M; Baseric T; Fettich J; Borsatti E
Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
[TBL] [Abstract][Full Text] [Related]
24. Comparison Between
Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
[TBL] [Abstract][Full Text] [Related]
25. Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer.
Haroon A; Syed R; Endozo R; Allie R; Freeman A; Emberton M; Bomanji J
Nucl Med Commun; 2017 May; 38(5):407-414. PubMed ID: 28379896
[TBL] [Abstract][Full Text] [Related]
26. Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
Chondrogiannis S; Marzola MC; Ferretti A; Maffione AM; Rampin L; Grassetto G; Nanni C; Colletti PM; Rubello D
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1356-64. PubMed ID: 23670521
[TBL] [Abstract][Full Text] [Related]
27. 10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.
Zattoni F; Ravelli I; Rensi M; Capobianco D; Borsatti E; Baresic T; Chiaravalloti A; Schillaci O; Alongi P; Bartolotta TV; Rambaldi I; Bartolomei M; Farsad M; Tredici M; Donner D; Chierichetti F; Trifirò G; Brugola E; Burei M; Dal Moro F; Cecchin D; Evangelista L
Clin Nucl Med; 2020 Aug; 45(8):594-603. PubMed ID: 32558711
[TBL] [Abstract][Full Text] [Related]
28. Lack of repeatability of radiomic features derived from PET scans: Results from a
Werner RA; Habacha B; Lütje S; Bundschuh L; Kosmala A; Essler M; Derlin T; Higuchi T; Lapa C; Buck AK; Pienta KJ; Lodge MA; Eisenberger MA; Markowski MC; Pomper MG; Gorin MA; Frey EC; Rowe SP; Bundschuh RA
Prostate; 2023 May; 83(6):547-554. PubMed ID: 36632656
[TBL] [Abstract][Full Text] [Related]
29.
Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
[TBL] [Abstract][Full Text] [Related]
30. "Real-world" evaluation of
Niziers V; Boissier R; Borchiellini D; Deville JL; Khoury C; Durand M; Toledano H; Albert T; Branger N; Bandelier Q; Ouvrier MJ; Gabriel S; Hoch B; Gross E; Walz J; Brenot-Rossi I; Pignot G
Urol Oncol; 2020 Jan; 38(1):2.e1-2.e9. PubMed ID: 31447087
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
32. Role of PET-CT with
Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
[TBL] [Abstract][Full Text] [Related]
33. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
Gacci M; Cai T; Siena G; Minervini A; Torshizi MF; Bartolini M; Giannì G; Saieva C; Ceroti M; Detti B; Livi L; Pupi A; Carini M
Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
[TBL] [Abstract][Full Text] [Related]
35. Effect of androgen deprivation therapy on intraprostatic tumour volume identified on
Chan J; Carver A; Brunt JN; Vinjamuri S; Syndikus I
Br J Radiol; 2017 Mar; 90(1071):20160818. PubMed ID: 27993093
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility and therapeutic impact of PET/CT [
Sánchez N; Valduvieco I; Ribal MJ; Campos F; Casas F; Nicolau C; Salvador R; Mellado B; Jorcano S; Fuster D; Paredes P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):284-291. PubMed ID: 32467000
[TBL] [Abstract][Full Text] [Related]
37. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
[TBL] [Abstract][Full Text] [Related]
38. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
39. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
40. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
